Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Consensus Target Price from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $20.83.

A number of research firms have issued reports on ALT. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Tuesday, March 18th. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC purchased a new position in shares of Altimmune during the third quarter valued at approximately $31,000. SBI Securities Co. Ltd. purchased a new position in Altimmune during the fourth quarter valued at $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune in the fourth quarter worth $60,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Altimmune in the fourth quarter worth $72,000. Finally, Sunbelt Securities Inc. increased its holdings in shares of Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after acquiring an additional 8,470 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

Shares of ALT stock opened at $5.32 on Friday. The business has a 50-day moving average of $6.24 and a 200 day moving average of $7.06. Altimmune has a 1-year low of $5.14 and a 1-year high of $11.16. The stock has a market capitalization of $409.71 million, a PE ratio of -3.43 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.